ReviewFrontiers in oncology2026
Perspectives on gastric cancer: the central role of gastrin in carcinogenesis by
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The function of the acid production in the upper gastrointestinal tract is to kill swallowed microorganisms and has been preserved in development since primitive fishes. However, acid production contributes to peptic ulcers and reflux esophagitis. Main body: Gastric acidity is sensed by the G cell producing gastrin, which regulates release of mediators from and proliferation of the enterochromaffin like (ECL) cell. Drugs inhibiting gastric acidity profoundly induce hypergastrinemia and were early shown to cause malignant tumors in rodents. In humans these drugs also lead to hypergastrinemia and ECL cell hyperplasia, but tumors have not been reported until more recently. Tumor latency depends on the natural life length of a species. H. pylori, the main cause of gastritis, peptic ulcer disease and gastric cancer, was early accepted as a carcinogen by WHO. However, no direct carcinogen was found and subsequently H. pylori carcinogenesis was shown to depend on development of oxyntic atrophy which is not compatible with being a direct carcinogen. H. pylori and autoimmunity are the main causes of oxyntic atrophy, hypoacidity, hypergastrinemia and gastric cancer. Conclusions: Gastrin is central in gastric carcinogenesis. H. pylori is the dominating cause of gastric cancer of both intestinal and diffuse types and H. pylori carcinogenesis may be explained by hypergastrinemia. A gastrin antagonist is long-awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.